Importance of FISH genetics in light chain amyloidosis.
作者信息
Gertz Morie A, Dispenzieri Angela, Muchtar Eli
机构信息
Morie A. Gertz: Division of Hematology, Mayo Clinic, Rochester, MN, USA.
出版信息
Oncotarget. 2017 Sep 19;8(47):81735-81736. doi: 10.18632/oncotarget.21052. eCollection 2017 Oct 10.
Abstract
摘要
相似文献
1
Importance of FISH genetics in light chain amyloidosis.荧光原位杂交（FISH）遗传学在轻链淀粉样变性中的重要性。
Oncotarget. 2017 Sep 19;8(47):81735-81736. doi: 10.18632/oncotarget.21052. eCollection 2017 Oct 10.
2
Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death.免疫球蛋白轻链淀粉样变性患者的异常荧光原位杂交是心脏受累和死亡的危险因素。
Blood Cancer J. 2015 May 1;5(5):e310. doi: 10.1038/bcj.2015.34.
3
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.易位 t(11;14)与硼替佐米为基础的方案治疗新诊断的 AL 淀粉样变性患者的不良预后相关。
J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.
4
Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.含硼替佐米方案治疗新诊断和复发的轻链型淀粉样变性：单中心经验
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e79-84. doi: 10.1016/j.clml.2016.03.005. Epub 2016 Mar 29.
5
[Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].[与单克隆丙种球蛋白病相关的肾脏疾病：诊断与治疗进展]
Presse Med. 2012 Mar;41(3 Pt 1):276-89. doi: 10.1016/j.lpm.2011.11.008. Epub 2012 Jan 13.
6
[Clinical benefits of bortezomib-containing regimens for newly diagnosed AL amyloidosis with severe cardiac impairment].含硼替佐米方案对新诊断的伴有严重心脏损害的AL淀粉样变性的临床益处
Rinsho Ketsueki. 2016 Aug;57(8):987-93. doi: 10.11406/rinketsu.57.987.
7
Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.硼替佐米、美法仑和泼尼松联合化疗用于新诊断的轻链（AL）淀粉样变性。
Amyloid. 2014 Dec;21(4):261-6. doi: 10.3109/13506129.2014.960560. Epub 2014 Sep 24.
8
Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.硼替佐米皮下注射联合方案治疗多发性骨髓瘤或系统性轻链淀粉样变性：新诊断患者的反应率和毒性的回顾性图表分析。
Clin Ther. 2013 Oct;35(10):1614-20. doi: 10.1016/j.clinthera.2013.08.015. Epub 2013 Sep 26.
9
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.一线硼替佐米治疗轻链型淀粉样变性患者的疗效：一项协作性回顾性多中心评估
Eur J Haematol. 2016 Feb;96(2):136-43. doi: 10.1111/ejh.12558. Epub 2015 Apr 17.
10
A patient with AL amyloidosis with negative free light chain results.一位有 AL 淀粉样变性且游离轻链检测结果为阴性的患者。
Clin Chem Lab Med. 2016 Jun 1;54(6):1035-7. doi: 10.1515/cclm-2015-0847.
引用本文的文献
1
Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement.分析伴有显性心脏或肾脏受累的 AL 淀粉样变性患者的完整 lambda 轻链胚系使用情况。
PLoS One. 2022 Feb 25;17(2):e0264407. doi: 10.1371/journal.pone.0264407. eCollection 2022.
2
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.2021 年免疫球蛋白轻链淀粉样变的诊断和治疗算法。
Blood Cancer J. 2021 May 15;11(5):90. doi: 10.1038/s41408-021-00483-7.
3
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.维奈托克可诱导 t(11;14)复发/难治性 AL 淀粉样变性的深度血液学缓解。
Blood Cancer J. 2021 Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w.
4
Immunoglobulin M Paraproteinaemias.免疫球蛋白M副蛋白血症
Cancers (Basel). 2020 Jun 25;12(6):1688. doi: 10.3390/cancers12061688.
5
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.2018 年免疫球蛋白轻链淀粉样变性诊断与治疗算法
Blood Cancer J. 2018 May 23;8(5):44. doi: 10.1038/s41408-018-0080-9.
本文引用的文献
1
The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.在尼泊尔帕坦医院，对伊马替尼治疗失败的费城染色体/BCR-ABL1阳性慢性髓性白血病患者进行伊马替尼耐药突变分析以指导治疗。
Br J Haematol. 2017 Jun;177(6):1000-1007. doi: 10.1111/bjh.14683. Epub 2017 May 3.
2
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category.未经治疗的 AL 淀粉样变性中间期荧光原位杂交的异常类型和治疗类别具有独立的预后影响。
Leukemia. 2017 Jul;31(7):1562-1569. doi: 10.1038/leu.2016.369. Epub 2016 Dec 1.
3
New investigational drugs with single-agent activity in multiple myeloma.在多发性骨髓瘤中具有单药活性的新型研究性药物。
Blood Cancer J. 2016 Jul 29;6(7):e451. doi: 10.1038/bcj.2016.53.
4
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统：国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
5
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.易位 t(11;14)与硼替佐米为基础的方案治疗新诊断的 AL 淀粉样变性患者的不良预后相关。
J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.
6
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.硼替佐米预处理和自体造血干细胞移植后可改善伴有 17p 缺失的多发性骨髓瘤患者的预后。
Blood. 2012 Jan 26;119(4):940-8. doi: 10.1182/blood-2011-09-379164. Epub 2011 Dec 8.
7
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.接受大剂量治疗的骨髓瘤患者中t(11;14)(q13;q32)、t(4;14)(p16.3;q32)和-17p13的临床意义
Blood. 2005 Oct 15;106(8):2837-40. doi: 10.1182/blood-2005-04-1411. Epub 2005 Jun 23.
Zotero 插件